STN: Text & Inventor's name Search

```
FILE 'HOME' ENTERED AT 15:43:23 ON 02 APR 2002

=> file medline
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 15:43:56 ON 02 APR 2002

 FILE LAST UPDATED: 1 APR 2002 (20020401/UP).  FILE COVERS 1958 TO DATE.

 On April 22, 2001, MEDLINE was reloaded.  See HELP RLOAD for details.

 MEDLINE now contains IN-PROCESS records.  See HELP CONTENT for details.

 MEDLINE is now updated 4 times per week.  A new current-awareness alert
 frequency (EVERYUPDATE) is available.  See HELP UPDATE for more information.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2001 vocabulary.  Enter HELP THESAURUS for details.

 The OLDMEDLINE file segment now contains data from 1958 through 1965.
 Enter HELP CONTENT for details.

 Left, right, and simultaneous left and right truncation are available in the
 Basic Index.  See HELP SFIELDS for details.

 THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE
 SUBSTANCE IDENTIFICATION.

=> s recombinant interferon and polymer and antioxidant?
        188299 RECOMBINANT
          4875 RECOMBINANTS
        190862 RECOMBINANT
                 (RECOMBINANT OR RECOMBINANTS)
         67884 INTERFERON
         17095 INTERFERONS
         72278 INTERFERON
                 (INTERFERON OR INTERFERONS)
          2384 RECOMBINANT INTERFERON
                 (RECOMBINANT(W)INTERFERON)
         17785 POLYMER
         30166 POLYMERS
         40938 POLYMER
                 (POLYMER OR POLYMERS)
         33802 ANTIOXIDANT?
L1           0 RECOMBINANT INTERFERON AND POLYMER AND ANTIOXIDANT?

=> s recombinant interferon and polymer and antioxidant
        188299 RECOMBINANT
          4875 RECOMBINANTS
        190862 RECOMBINANT
                 (RECOMBINANT OR RECOMBINANTS)
         67884 INTERFERON
         17095 INTERFERONS
         72278 INTERFERON
                 (INTERFERON OR INTERFERONS)
          2384 RECOMBINANT INTERFERON
                 (RECOMBINANT(W)INTERFERON)
         17785 POLYMER
         30166 POLYMERS
         40938 POLYMER
                 (POLYMER OR POLYMERS)
         20999 ANTIOXIDANT
         24083 ANTIOXIDANTS
         33797 ANTIOXIDANT
                 (ANTIOXIDANT OR ANTIOXIDANTS)
```

L2 0 RECOMBINANT INTERF[redacted]N AND POLYMER AND ANTIOXIDANT [redacted]

=> s recombinant interferon and polymer
188299 RECOMBINANT
4875 RECOMBINANTS
190862 RECOMBINANT
(RECOMBINANT OR RECOMBINANTS)
67884 INTERFERON
17095 INTERFERONS
72278 INTERFERON
(INTERFERON OR INTERFERONS)
2384 RECOMBINANT INTERFERON
(RECOMBINANT(W)INTERFERON)
17785 POLYMER
30166 POLYMERS
40938 POLYMER
(POLYMER OR POLYMERS)
L3 4 RECOMBINANT INTERFERON AND POLYMER

=> d L3 1-3

L3 ANSWER 1 OF 4 MEDLINE
AN 97320978 MEDLINE
DN 97320978 PubMed ID: 9177709
TI Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity.
AU Monkarsh S P; Ma Y; Aglione A; Bailon P; Ciolek D; DeBarbieri B; Graves M C; Hollfelder K; Michel H; Palleroni A; Porter J E; Russoman E; Roy S; Pan Y C
CS Department of Biopharmaceuticals, Hoffmann-La Roche Inc., Nutley, New Jersey 07110, USA.
SO ANALYTICAL BIOCHEMISTRY, (1997 May 1) 247 (2) 434-40.
Journal code: 4NK; 0370535. ISSN: 0003-2697.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199707
ED Entered STN: 19970721
Last Updated on STN: 19970721
Entered Medline: 19970710

L3 ANSWER 2 OF 4 MEDLINE
AN 97005215 MEDLINE
DN 97005215 PubMed ID: 8852526
TI Newer versus older treatments for relapsing-remitting multiple sclerosis.
AU Weinstock-Guttman B; Cohen J A
CS Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Ohio, USA.
SO DRUG SAFETY, (1996 Feb) 14 (2) 121-30. Ref: 22
Journal code: AHQ; 9002928. ISSN: 0114-5916.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199612
ED Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961212

L3 ANSWER 3 OF 4 MEDLINE
AN 89168263 MEDLINE
DN 89168263 PubMed ID: 2493987
TI Tumor cytotoxicity of human monocyte membrane-bound interleukin-1 alpha induced by synergistic actions of interferon-gamma and synthetic acyltripeptide, FK-565.

AU Inamura N; Sone S; Okubo A; [redacted]ishige E; Nakanishi M; Ogura T[redacted]
CS Third Department of Internal Medicine, University of Tokushima School of Medicine, Japan.
SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1989) 28 (3) 164-70.
Journal code: CN3; 8605732. ISSN: 0340-7004.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198905
ED Entered STN: 19900306
Last Updated on STN: 19900306
Entered Medline: 19890508

=> s recombinant interferon and PVP
188299 RECOMBINANT
4875 RECOMBINANTS
190862 RECOMBINANT
(RECOMBINANT OR RECOMBINANTS)
67884 INTERFERON
17095 INTERFERONS
72278 INTERFERON
(INTERFERON OR INTERFERONS)
2384 RECOMBINANT INTERFERON
(RECOMBINANT(W)INTERFERON)
1321 PVP
10 PVPS
1327 PVP
(PVP OR PVPS)
L4 0 RECOMBINANT INTERFERON AND PVP

=> s recombinant interferon and PVP
188299 RECOMBINANT
4875 RECOMBINANTS
190862 RECOMBINANT
(RECOMBINANT OR RECOMBINANTS)
67884 INTERFERON
17095 INTERFERONS
72278 INTERFERON
(INTERFERON OR INTERFERONS)
2384 RECOMBINANT INTERFERON
(RECOMBINANT(W)INTERFERON)
1321 PVP
10 PVPS
1327 PVP
(PVP OR PVPS)
L5 0 RECOMBINANT INTERFERON AND PVP

=> s interferon and PVP
67884 INTERFERON
17095 INTERFERONS
72278 INTERFERON
(INTERFERON OR INTERFERONS)
1321 PVP
10 PVPS
1327 PVP
(PVP OR PVPS)
L6 6 INTERFERON AND PVP

=> d L6 1-6

L6 ANSWER 1 OF 6 MEDLINE
AN 2001009587 MEDLINE
DN 20444493 PubMed ID: 10986558
TI Combination of interleukin 12 and **interferon** alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.

AU Mendiratta S K; Quezada A; M[redacted]r M; Thull N M; Bishop J S; No[redacted]trom J L; Pericle F
CS Valentis, Inc., The Woodlands, TX 77381, USA.
SO HUMAN GENE THERAPY, (2000 Sep 1) 11 (13) 1851-62.
Journal code: A12. ISSN: 1043-0342.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200010
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001026

L6 ANSWER 2 OF 6 MEDLINE
AN 2000227756 MEDLINE
DN 20227756 PubMed ID: 10762565
TI Biomaterial-associated persistence of Staphylococcus epidermidis in pericatheter macrophages.
AU Boelens J J; Dankert J; Murk J L; Weening J J; van der Poll T; Dingemans K P; Koole L; Laman J D; Zaat S A
CS Dept. of Pediatrics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.. Boelensjj@yahoo.com
SO JOURNAL OF INFECTIOUS DISEASES, (2000 Apr) 181 (4) 1337-49.
Journal code: IH3; 0413675. ISSN: 0022-1899.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200006
ED Entered STN: 20000613
Last Updated on STN: 20000613
Entered Medline: 20000601

L6 ANSWER 3 OF 6 MEDLINE
AN 1999434733 MEDLINE
DN 99434733 PubMed ID: 10505108
TI Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
AU Mendiratta S K; Quezada A; Matar M; Wang J; Hebel H L; Long S; Nordstrom J L; Pericle F
CS GeneMedicine, Inc. The Woodlands, TX 77381-4248, USA.
SO GENE THERAPY, (1999 May) 6 (5) 833-9.
Journal code: CCE; 9421525. ISSN: 0969-7128.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199910
ED Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991022

L6 ANSWER 4 OF 6 MEDLINE
AN 1999008308 MEDLINE
DN 99008308 PubMed ID: 9794206
TI Nonviral **interferon** alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response.
AU Coleman M; Muller S; Quezada A; Mendiratta S K; Wang J; Thull N M; Bishop J; Matar M; Mester J; Pericle F
CS GeneMedicine, Inc., The Woodlands, TX 77381-4248, USA.
SO HUMAN GENE THERAPY, (1998 Oct 10) 9 (15) 2223-30.
Journal code: A12; 9008950. ISSN: 1043-0342.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199901

ED Entered STN: 19990115
Last Updated on STN: 19990115
Entered Medline: 19990105

L6 ANSWER 5 OF 6 MEDLINE
AN 93170852 MEDLINE
DN 93170852 PubMed ID: 7679660
TI B-cell activation following murine cytomegalovirus infection: implications for autoimmunity.
AU Price P; Olver S D; Gibbons A E; Shellam G R
CS Department of Microbiology, University of Western Australia, Nedlands.
SO IMMUNOLOGY, (1993 Jan) 78 (1) 14-21.
Journal code: GH7; 0374672. ISSN: 0019-2805.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199303
ED Entered STN: 19930402
Last Updated on STN: 19960129
Entered Medline: 19930324

L6 ANSWER 6 OF 6 MEDLINE
AN 91108079 MEDLINE
DN 91108079 PubMed ID: 2125618
TI A method for preparing biologically active aqueous cyclosporin A solutions avoiding the use of detergents or organic solvents.
AU Yonish-Rouach E; Shinitzky M; Rubinstein M
CS Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel.
SO JOURNAL OF IMMUNOLOGICAL METHODS, (1990 Dec 31) 135 (1-2) 147-53.
Journal code: IFE; 1305440. ISSN: 0022-1759.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199102
ED Entered STN: 19910329
Last Updated on STN: 19980206
Entered Medline: 19910227

=> s interferon and nasal drop?
67884 INTERFERON
17095 INTERFERONS
72278 INTERFERON
(INTERFERON OR INTERFERONS)
47137 NASAL
49 NASALS
47165 NASAL
(NASAL OR NASALS)
55518 DROP?
125 NASAL DROP?
(NASAL(W)DROP?)
L7 5 INTERFERON AND NASAL DROP?

=> d L7 1-5

L7 ANSWER 1 OF 5 MEDLINE
AN 92368579 MEDLINE
DN 92368579 PubMed ID: 1323974
TI Otologic effects of **interferon** beta serine in experimental rhinovirus colds.
AU Sperber S J; Doyle W J; McBride T P; Sorrentino J V; Riker D K; Hayden F G
CS Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville.
NC T32AI-07046 (NIAID)
SO ARCHIVES OF OTOLARYNGOLOGY -- HEAD AND NECK SURGERY, (1992 Sep) 118 (9)

933-6.
Journal code: ALQ; 8603209. ISSN: 0886-4470.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199209
ED Entered STN: 19921009
Last Updated on STN: 19960129
Entered Medline: 19920922

L7 ANSWER 2 OF 5 MEDLINE
AN 90010266 MEDLINE
DN 90010266 PubMed ID: 2551976
TI Ineffectiveness of recombinant **interferon**-beta serine **nasal drops** for prophylaxis of natural colds.
AU Sperber S J; Levine P A; Sorrentino J V; Riker D K; Hayden F G
CS Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville.
NC T32AI-07046 (NIAID)
SO JOURNAL OF INFECTIOUS DISEASES, (1989 Oct) 160 (4) 700-5.
Journal code: IH3; 0413675. ISSN: 0022-1899.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198910
ED Entered STN: 19900328
Last Updated on STN: 19970203
Entered Medline: 19891028

L7 ANSWER 3 OF 5 MEDLINE
AN 88274084 MEDLINE
DN 88274084 PubMed ID: 2839579
TI Tolerance and efficacy of intranasal administration of recombinant beta serine **interferon** in healthy adults.
AU Sperber S J; Levine P A; Innes D J; Mills S E; Hayden F G
CS Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville.
NC T32AI-07046 (NIAID)
SO JOURNAL OF INFECTIOUS DISEASES, (1988 Jul) 158 (1) 166-75.
Journal code: IH3; 0413675. ISSN: 0022-1899.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198808
ED Entered STN: 19900308
Last Updated on STN: 19970203
Entered Medline: 19880817

L7 ANSWER 4 OF 5 MEDLINE
AN 84290843 MEDLINE
DN 84290843 PubMed ID: 6381610
TI Intranasal **interferon**-alpha 2 treatment of experimental rhinoviral colds.
AU Hayden F G; Gwaltney J M Jr
NC R23-AI-17034 (NIAID)
SO JOURNAL OF INFECTIOUS DISEASES, (1984 Aug) 150 (2) 174-80.
Journal code: IH3; 0413675. ISSN: 0022-1899.
CY United States
DT (CLINICAL TRIAL)

Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198410
ED Entered STN: 19900320
Last Updated on STN: 19970203
Entered Medline: 19841015

L7 ANSWER 5 OF 5 MEDLINE
AN 75196707 MEDLINE
DN 75196707 PubMed ID: 1170566
TI Induction of **interferon** in man by vaccines.
AU Rytel M W
SO PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, (1975 May) 149 (1) 266-70.
Journal code: PXZ; 7505892. ISSN: 0037-9727.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197509
ED Entered STN: 19900310
Last Updated on STN: 19900310
Entered Medline: 19750929

=> s recombinant interferon and antioxidant?
188299 RECOMBINANT
4875 RECOMBINANTS
190862 RECOMBINANT
(RECOMBINANT OR RECOMBINANTS)
67884 INTERFERON
17095 INTERFERONS
72278 INTERFERON
(INTERFERON OR INTERFERONS)
2384 RECOMBINANT INTERFERON
(RECOMBINANT(W)INTERFERON)
33802 ANTIOXIDANT?
L8 4 RECOMBINANT INTERFERON AND ANTIOXIDANT?

=> d L8 1-4

L8 ANSWER 1 OF 4 MEDLINE
AN 1999295021 MEDLINE
DN 99295021 PubMed ID: 10366945
TI [Strategy and tactics of radiation protection of the personnel in light of future work on stabilization and reorganization of the "Shelter" compound into radiologically safe system].
Strategiia i taktika radiologicheskoi zashchity personala v sviazi s predstoiashchimi rabotami po stabilizatsii i reorganizatsii ob''ekta "Ukrytie" v radiatsionno bezopasnuiu sistemu.
AU Seniuk O F; Danilov V M
CS ISTC Shelter NAcSci of Ukraine, Chernobyl.
SO RADIATSIONNAIA BIOLOGIIA, RADIOECOLOGIIA, (1999 Mar-Jun) 39 (2-3) 227-37.
Journal code: BWZ; 9317212. ISSN: 0869-8031.
CY RUSSIA: Russian Federation
DT Journal; Article; (JOURNAL ARTICLE)
LA Russian
FS Priority Journals
EM 199907
ED Entered STN: 19990714
Last Updated on STN: 19990714
Entered Medline: 19990701

L8 ANSWER 2 OF 4 MEDLINE
AN 94350232 MEDLINE
DN 94350232 PubMed ID: 8070686

TI Influenza virus induces expr[redacted]ion of **antioxidant** genes in hu[redacted]
epithelial cells.
AU Jacoby D B; Choi A M
CS Division of Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224.
NC AG00516 (NIA)
HL47126 (NHLBI)
SO FREE RADICAL BIOLOGY AND MEDICINE, (1994 Jun) 16 (6) 821-4.
Journal code: FRE; 8709159. ISSN: 0891-5849.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199409
ED Entered STN: 19941006
Last Updated on STN: 19941006
Entered Medline: 19940926

L8 ANSWER 3 OF 4 MEDLINE
AN 92310903 MEDLINE
DN 92310903 PubMed ID: 1614804
TI [Effectiveness of using **recombinant interferon** alfa2 (reaferon) combined with **antioxidants** in children with acute hepatitis B].
Effektivnost' primeneniia rekombinantnogo alfa2 interferona (reaferona) v komplekse s antioksidantami pri ostrom virusnom gepatite B u detei.
AU Reizis A R; Malinovskaia V V; Shekhade S; Drondina A K; Nikitina T S; Markarian A S; Nazarenko I V; Mikhailov M I
SO PEDIATRIIA, (1992) (1) 60-4.
Journal code: OYL; 0405563. ISSN: 0031-403X.
CY USSR
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA Russian
FS Priority Journals
EM 199207
ED Entered STN: 19920807
Last Updated on STN: 20000303
Entered Medline: 19920727

L8 ANSWER 4 OF 4 MEDLINE
AN 86306105 MEDLINE
DN 86306105 PubMed ID: 3018103
TI Induction of xanthine oxidase and heme oxygenase and depression of liver drug metabolism by interferon: a study with different **recombinant interferons**.
AU Ghezzi P; Saccardo B; Bianchi M
SO JOURNAL OF INTERFERON RESEARCH, (1986 Jun) 6 (3) 251-6.
Journal code: IJI; 8100396. ISSN: 0197-8357.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198610
ED Entered STN: 19900321
Last Updated on STN: 19980206
Entered Medline: 19861023

=> s (Gaponjuk, P? or Gaponjuk P?)/au
0 GAPONJUK, P?/AU
0 GAPONJUK P?/AU
L9 0 (GAPONJUK, P? OR GAPONJUK P?)/AU

East: interferon and ([redacted] or polyethylene adj1 oxide) and antioxidant?

	U	1	Document ID	Issue Date	Pages	Title	Current OR
1	☐	☐	US 4606917 A	19860819	7	Synergistic antiviral composition	424/85.6
2	☒	☐	US 4857316 A	19890815	7	Synergistic antiviral composition	424/85.6
3	☒	☐	US 5232712 A	19930803	9	Extrusion apparatus and systems	425/133.1
4	☐	☐	US 5334612 A	19940802	14	Pharmaceutical compositions containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses	514/440
5	☐	☐	US 5380754 A	19950110	13	Topical composition enhancing healing of viral lesions	514/513
6	☐	☐	US 5418154 A	19950523	21	Method of preparing elongated seamless capsules containing biological material	435/182
7	☒	☐	US 5472706 A	19951205	10	Dry compositions for preparing submicron emulsions	424/450
8	☒	☐	US 5542935 A	19960806	66	Therapeutic delivery systems related applications	604/190
9	☒	☐	US 5554148 A	19960910	20	Renewable neural implant device and method	604/890.1
10	☒	☐	US 5559156 A	19960924	8	Method for treating animals infected with Babesia spp.	514/682
11	☒	☐	US 5561164 A	19961001	8	Method of treatng protozoal infections caused by microsporidia	514/682
12	☒	☐	US 5567738 A	19961022	6	Use of 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-Naphthoquinone for the treatment of cancer	514/682
13	☒	☐	US 5569670 A	19961029	11	Combination medications containing alpha-lipoic acid and related	514/440

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1	435/70.5; 435/804		Eppstein, Deborah A.	☒	☐	☐	☐	☐	☐	☐
2	424/85.4		Eppstein, Deborah A.	☐	☐	☐	☐	☐	☐	☐
3	425/70		Mills, John F. et al.	☐	☐	☐	☐	☐	☐	☐
4	424/439; 514/557; 514/558; 514/559; 514/707		Kalden, Joachim et al.	☒	☐	☐	☐	☐	☐	☐
5	514/934		Miller, Bruce W. et al.	☒	☐	☐	☐	☐	☐	☐
6	264/4; 264/4.7; 424/451; 425/382R; 425/382.2; 435/178; 435/179; 530/817		Aebischer, Patrick et al.	☒	☐	☐	☐	☐	☐	☐
7	264/4.1; 264/4.3; 514/937; 514/938; 514/939; 514/943		Friedman, Doron et al.	☐	☐	☐	☐	☐	☐	☐
8	424/450; 600/458		Unger, Evan C. et al.	☐	☐	☐	☐	☐	☐	☐
9	604/265; 604/43; 604/93.01		Aebischer, Patrick et al.	☐	☐	☐	☐	☐	☐	☐
10			Gutteridge, Winston E. et al.	☐	☐	☐	☐	☐	☐	☐
11			Gutteridge, Winston E. et al.	☐	☐	☐	☐	☐	☐	☐
12			Hudson, Alan T.	☐	☐	☐	☐	☐	☐	☐
13	514/866		Weischer, Carl-Heinrich et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
1	US 4606917	☐
2	US 4857316	☐
3	US 5232712	☐
4	US 5334612	☐
5	US 5380754	☐
6	US 5418154	☐
7	US 5472706	☐
8	US 5542935	☐
9	US 5554148	☐
10	US 5559156	☐
11	US 5561164	☐
12	US 5567738	☐
13	US 5569670	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
14	☐	☐	US 5578567 A	19961126	11	Nasal pharmaceutical composition	514/12
15	☒	☐	US 5580575 A	19961203	55	Therapeutic drug delivery systems	424/450
16	☒	☐	US 5603955 A	19970218	20	Enhanced loading of solutes into polymer gels	424/484
17	☒	☐	US 5613958 A	19970325	25	Transdermal delivery systems for the modulated administration of drugs	604/307
18	☒	☐	US 5618528 A	19970408	18	Biologically compatible linear block copolymers of polyalkylene oxide and peptide units	424/78.3
19	☒	☐	US 5643773 A	19970701	19	Preparation of elongated seamless capsules containing a coaxial rod and biological material	435/182
20	☒	☐	US 5652274 A	19970729	172	Therapeutic-wound healing compositions and methods for preparing and using same	514/724
21	☐	☐	US 5656289 A	19970812	23	Pharmaceutical formulations that have a biologically active hydrophilic phase and a chylomicra-containing hydrophobic phase	424/455

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
14	530/324		Cardinaux, Fran.cedilla.ois et al.	☒	☐	☐	☐	☐	☐	☐
15			Unger, Evan C. et al.	☐	☐	☐	☐	☐	☐	☐
16	424/486; 424/487; 424/488; 514/944; 516/102; 516/104; 516/105; 516/106; 516/107		Gehrke, Stevin H. et al.	☐	☐	☐	☐	☐	☐	☐
17	424/449; 514/947; 602/52; 602/54; 602/58; 604/890.1		Kochinke, Frank et al.	☐	☐	☐	☐	☐	☐	☐
18	424/78.38; 525/423; 525/430; 525/54.1		Cooper, Eugene R. et al.	☐	☐	☐	☐	☐	☐	☐
19	264/4; 264/4.7; 424/451; 425/382R; 425/382.2; 435/178; 435/179; 435/325; 435/368; 435/382; 530/817		Aebischer, Patrick et al.	☐	☐	☐	☐	☐	☐	☐
20	514/461; 514/562; 514/567; 514/725; 514/774; 514/784		Martin, Alain	☐	☐	☐	☐	☐	☐	☐
21	424/450; 424/451; 424/456; 424/463; 514/2; 514/21; 514/3; 514/866; 514/937; 514/938; 514/941; 514/943		Cho, Young W. et al.	☒	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
14	US 5578567	☐
15	US 5580575	☐
16	US 5603955	☐
17	US 5613958	☐
18	US 5618528	☐
19	US 5643773	☐
20	US 5652274	☐
21	US 5656289	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
22	☒	☐	US 5672359 A	19970930	13	Multicompartment hard capsule with control release properties	424/463
23	☐	☐	US 5696160 A	19971209	13	Topical composition enhancing healing of viral lesions	514/513
24	☒	☐	US 5716981 A	19980210	121	Anti-angiogenic compositions and methods of use	514/449
25	☒	☐	US 5728735 A	19980317	7	Pharmaceutical composition containing R-.alpha.-lipoic acid or S-.alpha.-lipoic acid as active ingredient	514/560
26	☒	☐	US 5750142 A	19980512	11	Dry compositions for preparing submicron emulsions	424/450
27	☒	☐	US 5770222 A	19980623	54	Therapeutic drug delivery systems	424/450
28	☒	☐	US 5773286 A	19980630	19	Inner supported biocompatible cell capsules	435/297.1
29	☒	☐	US 5780514 A	19980714	8	Antiprotozoal medicaments	514/682

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
22	424/408; 424/452; 424/453; 424/454; 424/455; 424/456		Digenis, George A. et al.	☐	☐	☐	☐	☐	☐	☐
23	514/934		Miller, Bruce W. et al.	☒	☐	☐	☐	☐	☐	☐
24	128/898; 526/304; 528/421; 604/20; 604/21; 604/269; 604/508; 606/198; 623/1.15		Hunter, William L. et al.	☐	☐	☐	☐	☐	☐	☐
25			Ulrich, Heinz et al.	☐	☐	☐	☐	☐	☐	☐
26	264/4.1; 264/4.3; 514/937; 514/938; 514/939; 514/943		Friedman, Doron et al.	☐	☐	☐	☐	☐	☐	☐
27	264/4.1; 264/4.3; 264/4.6; 424/1.21; 424/489; 424/9.321; 424/9.51; 436/829		Unger, Evan C. et al.	☐	☐	☐	☐	☐	☐	☐
28	424/93.7; 435/174; 435/182; 435/289.1; 435/382; 435/395; 604/890.1		Dionne, Keith E. et al.	☐	☐	☐	☐	☐	☐	☐
29			Gutteridge, Winston Edward et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
22	US 5672359	☐
23	US 5696160	☐
24	US 5716981	☐
25	US 5728735	☐
26	US 5750142	☐
27	US 5770222	☐
28	US 5773286	☐
29	US 5780514	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
30	☒	☐	US 5786216 A	19980728	23	Inner-supported, biocompatible cell capsules	435/402
31	☒	☐	US 5840338 A	19981124	53	Loading of biologically active solutes into polymer gels	424/488
32	☒	☐	US 5849800 A	19981215	9	Use of amantadine for treatment of Hepatitis C	514/647
33	☒	☐	US 5853713 A	19981229	18	Biologically compatible linear block copolymers of polyalkylene oxide and peptide units	424/78.38
34	☒	☐	US 5856362 A	19990105	6	Medicaments for the treatment of toxoplasmosis	514/682
35	☒	☐	US 5886026 A	19990323	120	Anti-angiogenic compositions and methods of use	514/449
36	☒	☐	US 5900238 A	19990504	14	Vaccine delivery system	424/184.1
37	☒	☐	US 5962477 A	19991005	51	Screening methods for cytokine inhibitors	514/327
38	☒	☐	US 5972369 A	19991026	12	Diffusional implantable delivery system	424/424
39	☒	☐	US 5994341 A	19991130	119	Anti-angiogenic Compositions and methods for the treatment of arthritis	514/449
40	☒	☐	US 5994372 A	19991130	64	Peripherally active anti-hyperalgesic opiates	514/327

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
30	424/422; 424/93.7; 435/182; 435/395; 435/400; 435/401; 604/890.1		Dionne, Keith E. et al.	☐	☐	☐	☐	☐	☐	☐
31	424/484; 424/486; 424/487; 514/944; 516/99		Roos, Eric J. et al.	☐	☐	☐	☐	☐	☐	☐
32			Smith, Jill P.	☐	☐	☐	☐	☐	☐	☐
33	514/773; 525/523; 525/54.11; 530/345		Cooper, Eugene R. et al.	☐	☐	☐	☐	☐	☐	☐
34	568/328		Hudson, Alan Thomas	☐	☐	☐	☐	☐	☐	☐
35			Hunter, William L. et al.	☐	☐	☐	☐	☐	☐	☐
36	424/185.1; 424/192.1; 424/198.1; 424/278.1; 424/489; 424/490; 424/496; 424/497; 424/85.2		Gombotz, Wayne R. et al.	☐	☐	☐	☐	☐	☐	☐
37	424/78.05		Mak, Vivian	☐	☐	☐	☐	☐	☐	☐
38	424/425; 604/892.1		Roorda, Wouter E. et al.	☐	☐	☐	☐	☐	☐	☐
39	514/250; 514/825; 514/886		Hunter, William L. et al.	☐	☐	☐	☐	☐	☐	☐
40			Yaksh, Tony L.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
30	US 5786216	☐
31	US 5840338	☐
32	US 5849800	☐
33	US 5853713	☐
34	US 5856362	☐
35	US 5886026	☐
36	US 5900238	☐
37	US 5962477	☐
38	US 5972369	☐
39	US 5994341	☐
40	US 5994372	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
41	☒	☐	US 6001606 A	19991214	117	Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby	435/69.5
42	☒	☐	US 6004582 A	19991221	14	Multi-layered osmotic device	424/473
43	☒	☐	US 6025158 A	20000215	240	Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies	435/69.1
44	☒	☐	US 6028169 A	20000222	105	Chemokine .beta.-6 antagonists	530/324
45	☒	☐	US 6046177 A	20000404	59	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations	514/58
46	☒	☐	US 6117980 A	20000912	138	Humanized anti-IL-8 monoclonal antibodies	530/387.3
47	☒	☐	US 6133426 A	20001017	240	Humanized anti-IL-8 monoclonal antibodies	530/388.23

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
41	424/85.1; 435/252.3; 435/254.11; 435/320.1; 435/325; 435/471; 435/71.2; 536/23.1; 536/23.5; 930/140		Ruben, Steven M. et al.	☐	☐	☐	☐	☐	☐	☐
42	424/468; 424/472; 424/474; 424/475; 424/476; 424/479; 424/482		Faour, Joaquina et al.	☐	☐	☐	☐	☐	☐	☐
43			Gonzalez, Tania N. et al.	☐	☐	☐	☐	☐	☐	☐
44	530/300; 530/397; 530/399		Kreider, Brent L. et al.	☐	☐	☐	☐	☐	☐	☐
45	514/778; 514/964; 514/965; 536/103		Stella, Valentino J. et al.	☐	☐	☐	☐	☐	☐	☐
46	424/133.1; 424/135.1; 424/145.1; 530/387.1; 530/388.23		Gonzalez, Tania N. et al.	☐	☐	☐	☐	☐	☐	☐
47	424/130.1; 424/139.1; 424/141.1; 424/142.1; 424/145.1; 530/387.1; 530/387.9; 530/388.1; 530/388.15; 530/389.1; 530/389.2		Gonzalez, Tania N. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
41	US 6001606	☐
42	US 6004582	☐
43	US 6025158	☐
44	US 6028169	☐
45	US 6046177	☐
46	US 6117980	☐
47	US 6133426	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
48	☒	☐	US 6139832 A	20001031	53	Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides	424/85.1
49	☒	☐	US 6156312 A	20001205	21	Agents, affecting the hyperactivated immunological effector cells	424/144.1
50	☒	☐	US 6169920 B1	20010102	14	Iontophoretic drug delivery apparatus	604/20
51	☒	☐	US 6174873 B1	20010116	12	Oral administration of adenosine analogs	514/45
52	☒	☐	US 6183752 B1	20010206	264	Restenosis/atherosclerosis diagnosis, prophylaxis and therapy	424/199.1
53	☒	☐	US 6190691 B1	20010220		Methods for treating inflammatory conditions	424/449
54	☒	☐	US 6194391 B1	20010227		3'-azido-2',3'-dideoxyuridine administration to treat HIV and related test protocol	514/50

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
48	435/252.3; 435/320.1; 435/325; 435/471; 435/69.5; 435/71.1; 435/71.2; 530/351; 536/23.5; 930/140		Li, Haodong et al.	☐	☐	☐	☐	☐	☐	☐
49			Leskovar, Peter	☐	☐	☐	☐	☐	☐	☐
50	607/152		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
51	424/457; 424/458; 424/460; 424/463; 424/464; 424/469; 424/470; 514/46; 514/821; 514/885; 514/908; 514/959; 514/963; 514/964		Wrenn, Jr., Simeon M.	☐	☐	☐	☐	☐	☐	☐
52	424/230.1; 424/277.1; 424/93.2; 435/320.1; 514/44		Epstein, Stephen E. et al.	☐	☐	☐	☐	☐	☐	☐
53	514/859; 514/861; 514/863; 514/886; 514/887; 604/20		Mak, Vivien H. W.	☐	☐	☐	☐	☐	☐	☐
54	435/6; 514/253.01 ; 514/263.23 ; 514/45; 514/46; 514/47; 514/48; 514/49; 514/51		Schinazi, Raymond F. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
48	US 6139832	☐
49	US 6156312	☐
50	US 6169920	☐
51	US 6174873	☐
52	US 6183752	☐
53		☐
54		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
55	☒	☐	US 6207665 B1	20010327		Piperazine derivatives and their use as anti-inflammatory agents	514/235.8
56	☒	☐	US 6248363 B1	20010619		Solid carriers for improved delivery of active ingredients in pharmaceutical compositions	424/497

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
55	514/252.11 ; 514/254.01 ; 514/254.02 ; 514/254.05 ; 514/254.08 ; 514/254.1; 514/255.01 ; 544/121; 544/231; 544/357; 544/366; 544/369; 544/370; 544/372; 544/373; 544/379; 544/391		Bauman, John G. et al.	☐	☐	☐	☐	☐	☐	☐
56	424/422; 424/427; 424/430; 424/433; 424/434; 424/435; 424/436; 424/441; 424/451; 424/457; 424/463; 424/464; 424/465; 424/466; 424/470; 424/474; 424/476; 424/482; 424/489; 424/490; 424/498; 514/772.3; 514/773; 514/779; 514/784; 514/785; 514/786		Patel, Mahesh V. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
55		☐
56		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
57	☒	☐	US 6271254 B1	20010807		Pharmaceutical compositions containing R-.alpha.-lipoic acid or S-.alpha.-lipoic acid as active ingredient	514/440
58	☒	☐	US 6280728 B1	20010828		Treatment of hepatitis C virus infection using a protease and a flavonoid	424/94.64
59	☒	☐	US 6294170 B1	20010925		Composition and method for treating inflammatory diseases	424/134.1
60	☒	☐	US 6294655 B1	20010925		Anti-interleukin-1 receptor antagonist antibodies and uses thereof	530/388.23
61	☒	☐	US 6309663 B1	20011030		Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents	424/450
62	☒	☐	US 6317629 B1	20011113		Iontophoretic drug delivery apparatus	604/20

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
57	548/144		Ulrich, Heinz et al.	☐	☐	☐	☐	☐	☐	☐
58	424/94.65; 514/21; 514/25; 514/27		Stauder, Gerhard et al.	☐	☐	☐	☐	☐	☐	☐
59	514/12; 530/324		Boone, Thomas C. et al.	☐	☐	☐	☐	☐	☐	☐
60	424/134.1; 424/139.1; 424/141.1; 424/145.1; 435/7.1; 436/501; 530/350; 530/387.9; 530/388.1; 530/388.15; 530/389.1; 530/391.1; 530/391.3; 536/23.5		Ford, John et al.	☐	☐	☐	☐	☐	☐	☐
61	424/435; 424/451; 424/455; 424/456; 424/463; 424/464; 424/489; 424/499; 424/502; 514/937; 514/938; 514/939; 514/940; 514/941; 514/942; 514/943; 514/975		Patel, Mahesh V. et al.	☐	☐	☐	☐	☐	☐	☐
62	439/86; 607/152; 607/153		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
57		☐
58		☐
59		☐
60		☐
61		☐
62		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
63	☒	☐	US 6322770 B1	20011127		Indazole vitronectin receptor antagonist pharmaceuticals	424/1.65
64	☒	☐	US 6335013 B1	20020101	98	Methods and materials relating to CD39-like polypeptides	424/94.61
65	☒	☐	US 6337072 B1	20020108	60	Interleukin-1 receptor antagonist and recombinant production thereof	424/198.1
66	☒	☐	US 6339141 B1	20020115	41	Interleukin-1 Hy2 materials and methods	530/351
67	☒	☐	US 6350431 B1	20020226	63	Compounds	424/9.6
68	☒	☐	US 6352721 B1	20020305	18	Combined diffusion/osmotic pumping drug delivery system	424/473
69	☐	☐	US 6365726 B1	20020402	62	Polynucleotides encoding IL-1 Hy2 polypeptides	536/23.52

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
63	424/1.11; 424/9.1; 424/9.3; 424/9.34; 530/300; 534/14; 548/361.1		Rajopadhye, Milind et al.	☐	☐	☐	☐	☐	☐	☐
64	514/12		Ford, John et al.	☐	☐	☐	☐	☐	☐	☐
65	424/1.69; 435/252.3; 435/320.1; 435/325; 435/69.1; 435/69.52; 514/2; 530/350; 530/351; 530/402; 536/23.5		Ford, John et al.	☐	☐	☐	☐	☐	☐	☐
66	424/143.1; 424/145.1; 424/85.2		Ballinger, Dennis G. et al.	☐	☐	☐	☐	☐	☐	☐
67	548/223; 549/402; 549/427; 549/455		Snow, Robert Allen et al.	☐	☐	☐	☐	☐	☐	☐
68	424/422; 424/423; 424/424; 424/427; 424/435; 424/436; 424/437; 424/468; 424/472; 514/772.3; 514/781; 514/784; 514/785; 514/786		Faour, Joaquina	☐	☐	☐	☐	☐	☐	☐
69	435/320.1; 435/69.1; 435/69.52; 536/23.1; 536/23.5; 536/24.31		Ballinger, Dennis G. et al.	☒	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
63		☐
64	US 6335013	☐
65	US 6337072	☐
66	US 6339141	☐
67	US 6350431	☐
68	US 6352721	☐
69	US 6365726	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
70	☐	☐	US 6365768 B1	20020402	57	Interleukin-1 and tumor necrosis factors-.alpha. modulators, syntheses of said modulators and methods of using modulators	560/117

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
70	560/116; 562/498; 562/499		Palladino, Michael et al.	☒	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
70	US 6365768	☐

East: recombinant adj1 interferon and polymer

	U	1	Document ID	Issue Date	Pages	Title	Current OR
1	☒	☐	US 4636383 A	19870113	6	Interferon-cyclaradine combination	424/85.7
2	☒	☐	US 4710376 A	19871201	11	Topical therapeutic composition containing oxidation inhibitor system	514/2
3	☒	☐	US 4894226 A	19900116	14	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation	424/85.2
4	☒	☐	US 4961969 A	19901009		Process for recovering microbially produced interferon-.beta.	435/69.51
5	☒	☐	US 4962091 A	19901009	14	Controlled release of macromolecular polypeptides	424/85.2
6	☒	☐	US 4966843 A	19901030		Expression of interferon genes in Chinese hamster ovary cells	435/69.51
7	☒	☐	US 5004605 A	19910402	12	Low pH pharmaceutical compositions of recombinant .beta.-interferon	424/85.6
8	☒	☐	US 5145677 A	19920908		Process for treatment of diseases	424/85.5

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1	424/85.4; 435/71.1		Nagabhushan, Tattanahali L. et al.	☐	☐	☐	☐	☐	☐	☐
2	424/85.4		Evans, Sean A. et al.	☐	☐	☐	☐	☐	☐	☐
3	424/179.1; 424/85.1; 424/85.4; 424/85.6		Aldwin, Lois et al.	☐	☐	☐	☐	☐	☐	☐
4	424/85.6; 530/351		Hershenson, Susan et al.	☐	☐	☐	☐	☐	☐	☐
5	424/130.1; 424/178.1; 424/184.1; 424/193.1; 424/499; 424/85.1; 424/85.4; 424/85.6; 514/2; 514/21; 514/964		Eppstein, Deborah A. et al.	☐	☐	☐	☐	☐	☐	☐
6	435/320.1; 435/360; 435/466; 435/70.1; 435/70.3; 435/70.5; 435/811; 536/23.5; 536/23.52; 536/24.1		McCormick, Francis P. et al.	☐	☐	☐	☐	☐	☐	☐
7	530/351		Hershenson, Susan et al.	☐	☐	☐	☐	☐	☐	☐
8	424/85.1; 424/85.2		von Eichborn, Johann-Friedrich et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
1	US 4636383	☐
2	US 4710376	☐
3	US 4894226	☐
4		☐
5	US 4962091	☐
6		☐
7	US 5004605	☐
8		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
9	☒	☐	US 5187150 A	19930216	5	Polyester-based composition for the controlled release of polypeptide medicinal substances	514/2
10	☒	☐	US 5324510 A	19940628		Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma	424/139.1
11	☒	☐	US 5376567 A	19941227		Expression of interferon genes in Chinese hamster ovary cells	435/320.1
12	☒	☐	US 5382657 A	19950117	12	Peg-interferon conjugates	530/351
13	☒	☐	US 5496266 A	19960305	14	Device and method of iontophoretic drug delivery	604/20
14	☒	☐	US 5539063 A	19960723	20	Polymer for making poly(ethylene glycol)-protein conjugates	525/403

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
9	424/426; 424/457; 424/459; 424/489; 424/490; 424/491; 514/12; 514/15; 514/21; 514/3; 514/866; 514/885; 514/886; 514/963; 514/965		Speiser, Peter et al.	☐	☐	☐	☐	☐	☐	☐
10	424/152.1; 424/153.1; 424/154.1; 530/388.22; 530/388.7; 530/388.85; 530/389.6; 530/866; 530/868		Wegner, Craig D. et al.	☐	☐	☐	☐	☐	☐	☐
11	424/85.4; 435/252.3; 435/358; 435/69.51; 435/91.41; 536/23.52		McCormick, Francis P. et al.	☐	☐	☐	☐	☐	☐	☐
12	424/85.4; 424/85.7; 530/409; 530/410; 546/300; 546/301; 558/270		Karasiewicz, Robert et al.	☐	☐	☐	☐	☐	☐	☐
13	604/19		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
14	546/300		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
9	US 5187150	☐
10		☐
11		☐
12	US 5382657	☐
13	US 5496266	☐
14	US 5539063	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
15	☒	☐	US 5559213 A	19960924	19	Polyethylene-protein conjugates	530/351
16	☒	☐	US 5593990 A	19970114		Methods and compositions for inhibition of angiogenesis	514/235.2
17	☒	☐	US 5595732 A	19970121	21	Polyethylene-protein conjugates	424/85.7
18	☒	☐	US 5632984 A	19970527	8	Method of treatment of macular degeneration	424/85.4
19	☒	☐	US 5647844 A	19970715	13	Device and method of iontophoretic drug delivery	604/20
20	☒	☐	US 5730983 A	19980324		Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma	424/185.1
21	☒	☐	US 5747646 A	19980505		Polyethylene-protein conjugates	530/351

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
15	424/85.1; 424/85.2; 424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐
16	514/321; 514/323; 514/417; 514/418; 514/825		D'Amato, Robert	☐	☐	☐	☐	☐	☐	☐
17	424/85.4; 435/188; 435/964; 514/12; 530/350; 530/351; 530/403; 530/405; 530/409; 530/816		Hakini, John et al.	☐	☐	☐	☐	☐	☐	☐
18	424/427; 424/85.7		Wong, Vernon G. et al.	☐	☐	☐	☐	☐	☐	☐
19	424/449		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
20	424/143.1; 424/144.1; 424/184.1; 424/198.1; 514/2; 514/8; 530/300; 530/388.22; 530/388.75; 530/395		Wegner, Craig D. et al.	☐	☐	☐	☐	☐	☐	☐
21	424/85.1; 424/85.2; 424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409; 564/23		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
15	US 5559213	☐
16		☐
17	US 5595732	☐
18	US 5632984	☐
19	US 5647844	☐
20		☐
21		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
22	☒	☐	US 5792834 A	19980811		Polyethylene-protein conjugates	530/351
23	☒	☐	US 5795779 A	19980818		Human interferon-.beta. (IFN-.beta.) produced in Chinese hamster ovary (CHO) cells	435/360
24	☒	☐	US 5811119 A	19980922		Formulation and use of carotenoids in treatment of cancer	424/450
25	☒	☐	US 5814599 A	19980929		Transdermal delivery of encapsulated drugs	514/3
26	☒	☐	US 5827819 A	19981027		Covalent polar lipid conjugates with neurologically active compounds for targeting	514/2
27	☒	☐	US 5834594 A	19981110		Polyethylene-protein conjugates	530/351
28	☒	☐	US 5849860 A	19981215		Polyethylene-protein conjugates	528/370
29	☒	☐	US 5857992 A	19990112	13	Device and method of iontophoretic drug delivery	604/20
30	☒	☐	US 5891679 A	19990406		TNF-alpha muteins and a process for preparing them	435/69.5
31	☒	☐	US 5947921 A	19990907		Chemical and physical enhancers and ultrasound for transdermal drug delivery	604/22

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
22	424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐
23	424/85.6; 435/69.51		McCormick, Francis P. et al.	☐	☐	☐	☐	☐	☐	☐
24			Mehta, Kapil et al.	☐	☐	☐	☐	☐	☐	☐
25	424/450; 600/309; 600/310; 600/573; 600/574; 604/20; 604/23; 604/304; 604/500; 604/892.1		Mitragotri, Samir S. et al.	☐	☐	☐	☐	☐	☐	☐
26	424/450; 514/649		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
27	424/85.4; 424/85.7; 435/188; 530/403; 530/405; 530/409		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐
28	546/300; 546/301		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐
29	607/115		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
30	424/85.1; 435/252.5; 435/320.1; 530/351; 536/23.5		Lucas, Rudolph et al.	☐	☐	☐	☐	☐	☐	☐
31	601/2		Johnson, Mark E. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
22		☐
23		☐
24		☐
25		☐
26		☐
27		☐
28		☐
29	US 5857992	☐
30		☐
31		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
32	☒	☐	US 5952451 A	19990914		Solution polymerization of high molecular weight poly(phosphoesters) in toluene	528/272
33	☒	☐	US 5965519 A	19991012		Covalent polar lipid conjugates with biologically-active compounds for use in salves	514/2
34	☒	☐	US 5972707 A	19991026		Gene delivery system	435/455
35	☒	☐	US 5993435 A	19991130	13	Device and method of iontophoretic drug delivery	604/501
36	☒	☐	US 5994388 A	19991130		Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis	514/416
37	☒	☐	US 6008318 A	19991228		Two-stage solution polymerization of high molecular weight poly(phosphoesters)	528/398
38	☒	☐	US 6024977 A	20000215		Covalent polar lipid conjugates with neurologically active compounds for targeting	424/450
39	☒	☐	US 6025337 A	20000215		Solid microparticles for gene delivery	514/44
40	☒	☐	US 6028099 A	20000222		Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization	514/434
41	☒	☐	US 6041253 A	20000321		Effect of electric field and ultrasound for transdermal drug delivery	604/20

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
32			Zhao, Zhong	☐	☐	☐	☐	☐	☐	☐
33	424/450; 514/51; 514/557; 514/78; 530/300; 530/329; 530/331; 536/26.8; 544/243; 564/153		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
34	435/320.1; 435/440; 514/44		Roy, Krishnendu et al.	☐	☐	☐	☐	☐	☐	☐
35	604/20		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
36	514/417; 514/418; 514/419; 548/472; 548/473; 548/480; 548/481		Udagawa, Taturo et al.	☐	☐	☐	☐	☐	☐	☐
37	528/400		Zhao, Zhong et al.	☐	☐	☐	☐	☐	☐	☐
38	514/2; 514/211.11; 514/217; 514/222.2; 514/223.5; 514/224.8; 514/227.5; 514/649		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
39	435/320.1; 435/440; 435/455		Truong, Vu L. et al.	☐	☐	☐	☐	☐	☐	☐
40	514/456; 514/912		de Juan, Jr., Eugene	☐	☐	☐	☐	☐	☐	☐
41	600/578; 604/22		Kost, Joseph et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
32		☐
33		☐
34		☐
35	US 5993435	☐
36		☐
37		☐
38		☐
39		☐
40		☐
41		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
42	☒	☐	US 6063759 A	20000516	35	Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting	514/2
43	☒	☐	US 6071948 A	20000606		Methods and compositions for inhibition of angiogenesis	514/416
44	☒	☐	US 6093391 A	20000725	25	Peptide copolymer compositions	424/85.1
45	☒	☐	US 6114355 A	20000905	25	Methods and compositions for inhibition of angiogenesis	514/323
46	☒	☐	US 6133309 A	20001017	11	Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists	514/432
47	☒	☐	US 6153212 A	20001128	19	Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same	424/426
48	☒	☐	US 6166173 A	20001226	39	Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same	528/398
49	☒	☐	US 6190315 B1	20010220	15	Sonophoretic enhanced transdermal transport	600/309
50	☒	☐	US 6200597 B1	20010313		Formulation and use of carotenoids in treatment of cancer	424/450

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
42	424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/814; 530/815		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
43			D'Amato, Robert	☐	☐	☐	☐	☐	☐	☐
44	424/182.1; 424/78.18; 424/94.3; 514/3; 514/723		Kabanov, Alexander V. et al.	☐	☐	☐	☐	☐	☐	☐
45			D'Amato, Robert	☐	☐	☐	☐	☐	☐	☐
46			Bollag, Werner et al.	☐	☐	☐	☐	☐	☐	☐
47	514/772.3		Mao, Hai-quan et al.	☐	☐	☐	☐	☐	☐	☐
48	424/426; 424/486; 424/78.37; 523/111; 523/113; 525/538; 528/352; 528/400; 623/924		Mao, Hai-Quan et al.	☐	☐	☐	☐	☐	☐	☐
49	604/22		Kost, Joseph et al.	☐	☐	☐	☐	☐	☐	☐
50	514/725		Mehta, Kapil et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
42	US 6063759	☐
43		☐
44	US 6093391	☐
45	US 6114355	☐
46	US 6133309	☐
47	US 6153212	☐
48	US 6166173	☐
49	US 6190315	☐
50		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
51	☒	☐	US 6200780 B1	20010313	52	Human interferon-.epsilon.(IFN-.epsilon.), a type I interferon	435/69.51
52	☒	☐	US 6207153 B1	20010327	56	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers	424/138.1
53	☒	☐	US 6228879 B1	20010508	31	Methods and compositions for inhibition of angiogenesis	514/416
54	☒	☐	US 6234990 B1	20010522	19	Ultrasound enhancement of transdermal transport	604/22
55	☒	☐	US 6235756 B1	20010522		Methods and compositions for inhibition of angiogenesis by thalidomide	514/323
56	☒	☐	US 6242481 B1	20010605		Methods for the inhibition of angiogenesis with arglabin	514/468
57	☒	☐	US 6264990 B1	20010724		Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity.	424/499

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
51	424/85.4; 435/252.3; 435/252.33; 435/254.2; 435/320.1; 435/325; 435/358; 530/351; 536/23.52		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐
52	424/141.1; 424/142.1; 424/155.1; 530/387.7; 530/388.8; 530/391.1; 530/391.3; 530/391.7		Dan, Michael D. et al.	☐	☐	☐	☐	☐	☐	☐
53			Green, Shawn J. et al.	☐	☐	☐	☐	☐	☐	☐
54			Rowe, Stephen et al.	☐	☐	☐	☐	☐	☐	☐
55			D'Amato, Robert	☐	☐	☐	☐	☐	☐	☐
56	514/473; 514/475		Udagawa, Taturo et al.	☐	☐	☐	☐	☐	☐	☐
57	424/489; 514/2		Knepp, Victoria Marie et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
51	US 6200780	☐
52	US 6207153	☐
53	US 6228879	☐
54	US 6234990	☐
55		☐
56		☐
57		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
58	☒	☐	US 6274635 B1	20010814		Alkylated resorcinol derivatives for the treatment of immune diseases	514/718
59	☒	☐	US 6277410 B1	20010821	29	Copolymer compositions for oral delivery	424/486
60	☒	☐	US 6277830 B1	20010821	13	5'-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon	514/43
61	☒	☐	US 6299869 B1	20011009	50	Human interferon-epsilon: a type I interferon	424/85.4
62	☒	☐	US 6299877 B1	20011009		Type I interferons	424/158.1

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
58	514/454; 514/456; 514/720; 514/730; 514/731; 568/626; 568/630; 568/648; 568/650; 568/651; 568/652; 568/658; 568/662; 568/716		Travis, Craig A.	☐	☐	☐	☐	☐	☐	☐
59	424/422; 514/772.1; 514/772.3		Kabanov, Alexander V. et al.	☐	☐	☐	☐	☐	☐	☐
60	424/85.4; 424/85.7; 514/2; 514/21; 514/894; 530/351		Ganguly, Ashit K. et al.	☐	☐	☐	☐	☐	☐	☐
61	435/252.33; 435/320.1; 435/325; 435/358; 435/69.1; 435/69.2; 435/69.51; 514/12; 514/2; 530/350; 530/351; 536/23.1; 536/23.52		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐
62	424/139.1; 424/145.1; 530/351; 530/387.9; 530/388.1; 530/388.23; 530/389.1		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
58		☐
59	US 6277410	☐
60	US 6277830	☐
61	US 6299869	☐
62		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
63	☒	☐	US 6300475 B1	20011009		Interferon PRO655	530/351
64	☒	☐	US 6312924 B1	20011106	44	Murine interferon-.alpha.	435/69.51
65	☒	☐	US 6322797 B1	20011127	40	Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same	424/78.37
66	☒	☐	US 6326397 B1	20011204	24	Retinoid antagonists and use thereof	514/531
67	☒	☐	US 6329175 B1	20011211	59	Interferon-.epsilon.	435/69.51

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
63	435/252.3; 435/252.33; 435/254.11; 435/254.2; 435/320.1; 435/325; 435/358; 435/69.51; 530/350; 536/23.1; 536/23.5; 536/23.52		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐
64	435/252.8; 435/254.11; 435/320.1; 435/325; 435/348; 435/349; 435/419; 435/70.5; 514/2; 530/351; 536/23.1; 536/23.52		Presnell, Scott R. et al.	☐	☐	☐	☐	☐	☐	☐
65	428/378; 442/248; 523/115; 528/398		Mao, Hai-Quan et al.	☐	☐	☐	☐	☐	☐	☐
66	514/502; 514/570; 554/218; 560/55; 560/59; 562/465; 562/469; 568/442		Bollag, Werner et al.	☐	☐	☐	☐	☐	☐	☐
67	435/252.3; 435/254.1; 435/255.1; 435/320.1; 435/325; 435/348; 435/349; 435/410; 530/351; 536/23.52		Conklin, Darrell C. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
63		☐
64	US 6312924	☐
65	US 6322797	☐
66	US 6326397	☐
67	US 6329175	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
68	☒	☐	US 6339060 B1	20020115	35	Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting	514/2
69	☐	☐	US 6362162 B1	20020326	7	CML Therapy	514/2

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
68	424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/814; 530/815		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
69			Rybak, Mary Ellen et al.	☒	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
68	US 6339060	☐
69	US 6362162	☐

East : interferon & polymer?

	U	1	Document ID	Issue Date	Pages	Title	Current OR
1	☐	☐	CN 1316436 A	20011010	NA	Process for preparing water-soluble slow-releasing recombination protein	
2	☐	☐	DD 275692 A	19900131	NA	Semi-plastic products redn. from poly-inosinic acid - and complementary nucleotide, useful as stable interferon inducers and killer cell activators	
3	☐	☐	DD 97428 A	N/A	NA	N-vinyl-nucleobase polymers - with biological activity	
4	☒	☐	DE 2359621 A	19750605	9	Antiviral mainly isotactic polyacrylic acid salts - prepd. by low temp. polymn. of branched-chain alkyl acrylates then saponification	
5	☒	☐	DE 3603444 A	19870806		Stabilised topical interferon alpha formulations - contain combination of e.g. cellulose derivs., gelatin and antiadhesion agent as stabiliser and carrier	
6	☒	☐	DE 3779221 G	20001122		Device administering dose of polypeptide into lungs - delivers suspension in gas of particles sized to penetrate into alveoli	
7	☒	☐	DE 3790487 C	19990331		Therapeutic agent encapsulated in proteinoid microspheres - for oral admin. to protect agent against gastrointestinal tract deactivation	
8	☒	☐	DE 3822406 A	19890112		Low molecular double-stranded rna prodn. - by calibration of single-strand ed nucleic acid polymers before annealing to give double-stranded product	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1			CHEN, H et al.	☒	☐	☐	☐	☐	☐	☐
2			GOTTSETEIN, H et al.	☒	☐	☐	☐	☐	☐	☐
3				☒	☐	☐	☐	☐	☐	☐
4				☐	☐	☐	☐	☐	☐	☐
5			FRANZ, H	☐	☐	☐	☐	☐	☐	☐
6			DAUGHERTY, A L	☐	☐	☐	☐	☐	☐	☐
7			ROSEN, R et al.	☐	☐	☐	☐	☐	☐	☐
8			JUNICHI, Y et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
1		☐
2		☐
3		☐
4	US 4150238	☐
5		☐
6		☐
7		☐
8		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
9	☒	☐	DE 3873712 G	19991110		Slow release compsn. for treating eye conditions - comprises drug microencapsulated in liposome or polymer	
10	☒	☐	DE 4406172 A	20000816		Branched polyester used as biodegradable depot matrix - prepd. from electrolyte-substd. poly:ol and poly-hydroxy-carboxylic acid, esp. for supplying peptide or protein, e.g. interleukin	
11	☒	☐	EP 138216 B	19850508		Sustained release injectable compsn. - consists of bio-degradable powder contg. the active ingredient suspended in viscous liq.	
12	☒	☐	EP 180567 A	19860507		Sepn. of poly:peptide fractions from soln. - by pptn. of one fraction with soluble charged polymer in presence of soluble neutral polymer for enhanced efficacy	
13	☒	☐	EP 197776 A	19861015		Prepn. of porous oxide or hydroxide bodies - by adding sol. of the oxide or hydroxide to fluid freezing medium then heating	
14	☒	☐	EP 36372 A	19810923		Partially deacylated N-acyl ganglioside(s) and glyco:lipid(s) - have free amine groups which may be used to couple to solid supports without loss of specific affinity	
15	☒	☐	EP 377477 A	19900711		Micro-encapsulation of bioactive substances by phase-sepn. - comprises dispersing substance in organic soln. of biocompatible polymer, adding phase separator and excess hardening agent	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
9			WONG, V G	☐	☐	☐	☐	☐	☐	☐
10			KISSEL, T et al.	☐	☐	☐	☐	☐	☐	☐
11			FUJIOKA, K et al.	☐	☐	☐	☐	☐	☐	☐
12			HO, S V	☐	☐	☐	☐	☐	☐	☐
13			PEPPER, D S	☐	☐	☐	☐	☐	☐	☐
14			COURT, G et al.	☐	☐	☐	☐	☐	☐	☐
15			GROENENDAAL, J W et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
9		☐
10		☐
11		☐
12		☐
13		☐
14		☐
15		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
16	☒	☐	EP 404062 A	19901227		New 2-oxy:germyl ethane sulphonate and sulphonamide polymers - useful as immunomodulators, interferon-prodn. enhancers and anti-tumour agents, and for treatment of AIDS	
17	☒	☐	EP 572942 A	20001129		Delayed release oral pharmaceutical compsn. for specific colon delivery - comprises core contg. active principles, intermediate swellable polymer coating delaying release and outer layer whose removal activates intermediate layer removal	
18	☒	☐	EP 58481 A	19820825		Compsn. of poly:lactide and acid stable poly:peptide - for use in aq. environment to release all polypeptide continuously	
19	☒	☐	EP 652223 A	19951011		New 3-oxy:germyl:propionic acid polymer - useful in treatment of, e.g., immune diseases caused by viruses	
20	☒	☐	EP 733067 B	20011206		N-terminally chemically modified proteins - partic. G-CSF or consensus interferon modified with polymers, esp. polyethylene glycol	
21	☒	☐	EP 978289 A	20000221		New virucide drug, especially for treating influenza contains iodine and lithium chloride	
22	☒	☐	FR 2279422 A	19760326		Antiviral interferon fixed to polysaccharide support - act on exterior of cells without effecting pathological processes inside cell	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
16			BABA, Y et al.	☐	☐	☐	☐	☐	☐	☐
17			BUSETTI, C et al.	☐	☐	☐	☐	☐	☐	☐
18			HUTCHINSON, F G	☐	☐	☐	☐	☐	☐	☐
19			MITANI, T et al.	☐	☐	☐	☐	☐	☐	☐
20			DEPRINCE, R B et al.	☐	☐	☐	☐	☐	☐	☐
21			ARAKELJAN, N G et al.	☐	☐	☐	☐	☐	☐	☐
22				☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
16		☐
17		☐
18		☐
19		☐
20		☐
21		☐
22		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
23	☒	☐	GB 2317340 B	19991214		Compsn. for delivery of active agent - has polymeric lamellar substrate particles at least in part crystalline, with adsorbed agent	
24	☒	☐	JP 03251599 A	19911111		Interferon-beta prodn. augmenting substances - are sugar-protein polymers used to treat infections caused by viruses, bacteria and fungi	
25	☒	☐	JP 05058877 A	20010709		Nasal drop or spray having high absorption - contains bioactive substance, sucrose fatty acid ester, and carboxy-vinyl! polymer	
26	☒	☐	JP 63196276 A	19880815		Base used in cell cultivation for prodn. of e.g. vaccine, etc. - comprise polymer base with micro phase separative structure and laminated with monomolecular layer	
27	☒	☐	JP 63196277 A	19880815		Base for cell culture with adhesive properties - comprises porous or hollow fibrous high mol. wt. polymer with ozone-treated surface supporting e.g. sugar or protein	
28	☒	☐	JP 63196278 A	19880815		Base for cultivation of cells - comprises hollow or porous fibres of high mol. wt. polymer with surface treated and supporting fibrin stripe, lattice etc.	
29	☒	☐	JP 63196279 A	19880815		Base for cell culture - comprises porous or hollow fibre high mol. wt. polymer supporting laminin glyco:protein	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
23			COOMBES, A G A et al.	☐	☐	☐	☐	☐	☐	☐
24				☐	☐	☐	☐	☐	☐	☐
25				☐	☐	☐	☐	☐	☐	☐
26				☐	☐	☐	☐	☐	☐	☐
27				☐	☐	☐	☐	☐	☐	☐
28				☐	☐	☐	☐	☐	☐	☐
29				☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
23		☐
24		☐
25		☐
26		☐
27		☐
28		☐
29		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
30	☒	☐	JP 63196281 A	19880815		Base for cell culture - comprises complex of high mol. wt. polymer with inorganic substance	
31	☒	☐	US 20010007758 A	20020205		Suppressing an autoimmune reaction in multiple sclerosis patients	
32	☒	☐	US 20010046487 A	20011129		Method of permeabilizing platelets useful for drug delivery involves treating isolated platelets with an acid	
33	☒	☐	US 3884845 A	19750520		Condensn polymers of polyethylenimine and pentachloropyridine - as interferon inducer and antiviral agent	
34	☒	☐	US 4189534 A	19800219		Cell culture microcarriers	
35	☒	☐	US 4293654 A	19811006		Cell culture microcarriers	
36	☒	☐	US 4710376 A	19871201		Stable topical compsn. contg. lymphokine - contains water soluble polymers one with reducing moieties and another with oxidising moieties covalently bound and aq. vehicle	
37	☒	☐	US 5004605 A	19910402		Low pH pharmaceutical compositions of recombinant beta -interferon	
38	☒	☐	US 5256570 A	19931026		Rotary biological contactor with supports enveloped in chamber - configured to support microorganisms or cells, pref. corrugated sheet media with drain holes rotatable in outer jacket	
39	☒	☐	US 5334379 A	19940802		Immunogenic conjugates of bacterial capsular polymers - linked to interferon or interleukin, useful in vaccines against bacterial infection	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
30				☐	☐	☐	☐	☐	☐	☐
31			MARON, R et al.	☐	☐	☐	☐	☐	☐	☐
32			ROSER, B J et al.	☐	☐	☐	☐	☐	☐	☐
33				☐	☐	☐	☐	☐	☐	☐
34			LEVINE, DAVID W et al.	☐	☐	☐	☐	☐	☐	☐
35			LEVINE, DAVID W et al.	☐	☐	☐	☐	☐	☐	☐
36			EVANS, S A et al.	☐	☐	☐	☐	☐	☐	☐
37			HERSHENSON, SUSAN et al.	☐	☐	☐	☐	☐	☐	☐
38			CLYDE, R A	☐	☐	☐	☐	☐	☐	☐
39			EBY, R et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
30		☐
31		☐
32		☐
33		☐
34		☐
35		☐
36		☐
37		☐
38		☐
39		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
40	☒	☐	US 5449720 A	19991020		New polymer complexes of biologically active peptide(s) or proteins - are used to amplify delivery of the active agent using the vitamin B12 uptake system	
41	☒	☐	US 5681811 A	19970213		Bioactive agent conjugates with hydrophilic or lipophilic polymers - having improved stability to degradation and passage through membranes, used with proteins, peptide(s), e.g., insulin, nucleotide(s), antibiotics, etc.	
42	☒	☐	US 5714166 A	19980203		Conjugates of dense star polymers - with therapeutic agents, diagnostic agents, agrochemicals, etc.	
43	☐	☐	US 5824784 A	19981020	30	N-terminally chemically modified protein compositions and methods	
44	☒	☐	US 6048736 A	20000411		Controlled release, targetable composition comprises the active agent, nucleic acid or toxin entrapped in a cyclodextrin polymer	
45	☒	☐	US 6221351 B	20020115		Use of staphylococcal enterotoxin(s) and homologues - for treating cancer in a patient or for the treatment of auto-immune diseases	
46	☒	☐	US 6342244 B	20011219		New hydrophilic polymers derivatized through a dithiobenzyl linkage to an amine-containing ligand such as polypeptide, lipid or drug, e.g. interferon, interleukin, growth factor or enzyme	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
40			GOULD, A R et al.	☐	☐	☐	☐	☐	☐	☐
41			EKWURIBE, N N	☐	☐	☐	☐	☐	☐	☐
42			BAKER, J R et al.	☐	☐	☐	☐	☐	☐	☐
43			KINSTLER, OLAF B et al.	☒	☐	☐	☐	☐	☐	☐
44			KOSAK, K M	☐	☐	☐	☐	☐	☐	☐
45			TERMAN, D S et al.	☐	☐	☐	☐	☐	☐	☐
46			ZALIPSKY, S et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
40		☐
41		☐
42		☐
43	US 5824784	☐
44		☐
45		☐
46		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
47	☒	☐	WO 200121229 A	20010329		Endovascular stents comprise stent material, antimicrobial agent and optional antiinflammatory agent, provide immediate mechanical support to maintain vessel patency and slowly release active agents	
48	☒	☐	WO 200141810 A	20010614		Nucleic acid delivery system which includes polymeric carrier particles which are electrically neutral and insoluble in body fluids, can achieve rapid release of nucleic acid into cells	
49	☒	☐	WO 9216555 A	19921001		Polypeptide(s) or glyco-polypeptide(s) conjugated to water-soluble polymers - contain hydrazine or hydrazone gp. and peptide that prevents crosslinking, preserving activity	
50	☒	☐	WO 9405332 A	19940317		New glycolated, glycosylated macromolecule derivs. - esp. polypeptide(s), having reduced immunogenicity without redn. of biological activity	
51	☒	☐	WO 9513090 A	19950518		Long-acting alpha-interferon polymer conjugates - prepd. in presence of surfactant for higher yield and activity, used e.g. as antiviral agents	
52	☒	☐	WO 9611953 A1	19960425		N-TERMINALLY CHEMICALLY MODIFIED PROTEIN COMPOSITIONS AND METHODS	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
47			LEE, C C	☐	☐	☐	☐	☐	☐	☐
48			GUAN, H	☐	☐	☐	☐	☐	☐	☐
49			LEE, C et al.	☐	☐	☐	☐	☐	☐	☐
50			MTIMKULU, T	☐	☐	☐	☐	☐	☐	☐
51			CHO, M et al.	☐	☐	☐	☐	☐	☐	☐
52			KINSTLER, OLAF B et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
47		☐
48		☐
49		☐
50		☐
51		☐
52		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
53	☒	☐	WO 9961032 A	20010525		Production of homogeneous and safe nucleic acid-containing composite preparation, with good quality, no coarse particles and capable of filtrative sterilization	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
53			HIRABAYASHI, K et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
53		☐

East: recombinant alpha interferon and polymer

	U	1	Document ID	Issue Date	Pages	Title	Current OR
1	☒	☐	US 4710376 A	19871201	11	Topical therapeutic composition containing oxidation inhibitor system	514/2
2	☒	☐	US 4894226 A	19900116		Solubilization of proteins for pharmaceutical compositions using polyproline conjugation	424/85.2
3	☒	☐	US 4962091 A	19901009		Controlled release of macromolecular polypeptides	424/85.2
4	☒	☐	US 5004605 A	19910402		Low pH pharmaceutical compositions of recombinant .beta.-interferon	424/85.6
5	☒	☐	US 5183746 A	19930202		Formulation processes for pharmaceutical compositions of recombinant .beta. -	435/69.51
6	☒	☐	US 5187150 A	19930216		Polyester-based composition for the controlled release of polypeptide medicinal substances	514/2
7	☒	☐	US 5196323 A	19930323		Process for preparing and purifying alpha-interferon	435/69.51

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1	424/85.4		Evans, Sean A. et al.	☐	☐	☐	☐	☐	☐	☐
2	424/179.1; 424/85.1; 424/85.4; 424/85.6		Aldwin, Lois et al.	☐	☐	☐	☐	☐	☐	☐
3	424/130.1; 424/178.1; 424/184.1; 424/193.1; 424/499; 424/85.1; 424/85.4; 424/85.6; 514/2; 514/21; 514/964		Eppstein, Deborah A. et al.	☐	☐	☐	☐	☐	☐	☐
4	530/351		Hershenson, Susan et al.	☐	☐	☐	☐	☐	☐	☐
5	424/85.6; 530/351		Shaked, Ze'Ev et al.	☐	☐	☐	☐	☐	☐	☐
6	424/426; 424/457; 424/459; 424/489; 424/490; 424/491; 514/12; 514/15; 514/21; 514/3; 514/866; 514/885; 514/886; 514/963; 514/965		Speiser, Peter et al.	☐	☐	☐	☐	☐	☐	☐
7	424/85.4; 424/85.7; 435/252.3; 530/351; 530/413; 530/416; 530/419		Bodo, Gerhard et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
1	US 4710376	☐
2		☐
3		☐
4		☐
5		☐
6		☐
7		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
8	☒	☐	US 5248769 A	19930928		Process for recovering refractile bodies containing heterologous proteins from microbial hosts	530/414
9	☒	☐	US 5286637 A	19940215		Biologically active drug polymer derivatives and method for preparing same	435/183
10	☒	☐	US 5310729 A	19940510		Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions	514/15
11	☒	☐	US 5382657 A	19950117		Peg-interferon conjugates	530/351
12	☒	☐	US 5496266 A	19960305		Device and method of iontophoretic drug delivery	604/20
13	☒	☐	US 5508031 A	19960416		Method for treating biological damage using a free-radial scavenger and interleukin-2	424/85.2
14	☒	☐	US 5539063 A	19960723		Polymer for making poly(ethylene glycol)-protein conjugates	525/403
15	☒	☐	US 5540923 A	19960730		Interferon proteins	424/85.5
16	☒	☐	US 5559213 A	19960924		Polyethylene-protein conjugates	530/351

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
8	435/69.1; 435/69.5; 435/69.51; 435/69.52; 530/351; 530/412; 530/427		Dorin, Glenn	☐	☐	☐	☐	☐	☐	☐
9	424/85.2; 424/94.4; 435/181; 435/189; 435/68.1; 435/832; 514/2; 530/397; 530/399		Veronese, Francesco et al.	☐	☐	☐	☐	☐	☐	☐
10	514/16; 530/327; 530/328		Lernhardt, Waldemar	☐	☐	☐	☐	☐	☐	☐
11	424/85.4; 424/85.7; 530/409; 530/410; 546/300; 546/301; 558/270		Karasiewicz, Robert et al.	☐	☐	☐	☐	☐	☐	☐
12	604/19		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
13	530/351		Zimmerman, Robert et al.	☐	☐	☐	☐	☐	☐	☐
14	546/300		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐
15	424/85.4; 424/85.6; 530/351		Ebbesen, Peter et al.	☐	☐	☐	☐	☐	☐	☐
16	424/85.1; 424/85.2; 424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
8		☐
9		☐
10		☐
11		☐
12		☐
13		☐
14		☐
15		☐
16		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
17	☒	☐	US 5595732 A	19970121		Polyethylene-protein conjugates	424/85.7
18	☒	☐	US 5614504 A	19970325		Method of making inosine monophosphate derivatives and immunopotentiating uses thereof	514/45
19	☒	☐	US 5632983 A	19970527		Method for treating secondary immunodeficiency	424/85.1
20	☒	☐	US 5632984 A	19970527		Method of treatment of macular degeneration	424/85.4
21	☒	☐	US 5647844 A	19970715		Device and method of iontophoretic drug delivery	604/20
22	☒	☐	US 5658565 A	19970819		Inducible nitric oxide synthase gene for treatment of disease	424/93.21
23	☒	☐	US 5667776 A	19970916		Treatment for biological damage using tumor necrosis factor and a free-radical scavenger	424/85.1
24	☒	☐	US 5698194 A	19971216		Method for making a medicament for treating secondary immunodeficiency	424/85.1
25	☒	☐	US 5702697 A	19971230		Treatment for biological damage using a colony stimulating factor and a biological modifier	424/85.1
26	☒	☐	US 5736154 A	19980407		Transdermal delivery system	424/449

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
17	424/85.4; 435/188; 435/964; 514/12; 530/350; 530/351; 530/403; 530/405; 530/409; 530/816		Hakini, John et al.	☐	☐	☐	☐	☐	☐	☐
18	536/26.7; 536/27.8		Hadden, John W. et al.	☐	☐	☐	☐	☐	☐	☐
19	424/85.2; 424/85.4; 514/21		Hadden, John W.	☐	☐	☐	☐	☐	☐	☐
20	424/427; 424/85.7		Wong, Vernon G. et al.	☐	☐	☐	☐	☐	☐	☐
21	424/449		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
22	424/93.1; 424/93.2; 435/189; 435/191; 435/235.1; 435/320.1; 514/44; 536/23.1; 536/23.2; 536/23.5		Billiar, Timothy R. et al.	☐	☐	☐	☐	☐	☐	☐
23	514/2; 514/263.31 ; 514/474; 514/550; 530/351		Zimmerman, Robert et al.	☐	☐	☐	☐	☐	☐	☐
24	424/85.2; 424/85.4; 424/85.5; 435/70.4; 435/70.5		Hadden, John Winthrop	☐	☐	☐	☐	☐	☐	☐
25	514/2; 514/8; 514/885; 530/351		Zimmerman, Robert et al.	☐	☐	☐	☐	☐	☐	☐
26	424/448		Fuisz, Richard C.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
17		☐
18		☐
19		☐
20		☐
21		☐
22		☐
23		☐
24		☐
25		☐
26		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
27	☒	☐	US 5747646 A	19980505		Polyethylene-protein conjugates	530/351
28	☒	☐	US 5756353 A	19980526		Expression of cloned genes in the lung by aerosol-and liposome-based delivery	514/44
29	☒	☐	US 5762920 A	19980609		Megakaryocyte production	424/85.1
30	☒	☐	US 5792834 A	19980811		Polyethylene-protein conjugates	530/351
31	☒	☐	US 5814599 A	19980929		Transdermal delivery of encapsulated drugs	514/3
32	☒	☐	US 5827819 A	19981027		Covalent polar lipid conjugates with neurologically active compounds for targeting	514/2
33	☒	☐	US 5834594 A	19981110		Polyethylene-protein conjugates	530/351

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
27	424/85.1; 424/85.2; 424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409; 564/23		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐
28	128/200.14 ; 424/450; 435/320.1; 435/375; 435/377; 435/458; 435/459; 435/6; 435/69.1; 435/91.1; 536/24.1		Debs, Robert J.	☐	☐	☐	☐	☐	☐	☐
29	424/85.2		Yung, Yee Pang et al.	☐	☐	☐	☐	☐	☐	☐
30	424/85.4; 424/85.7; 435/188; 530/350; 530/403; 530/405; 530/409		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐
31	424/450; 600/309; 600/310; 600/573; 600/574; 604/20; 604/23; 604/304; 604/500; 604/892.1		Mitragotri, Samir S. et al.	☐	☐	☐	☐	☐	☐	☐
32	424/450; 514/649		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
33	424/85.4; 424/85.7; 435/188; 530/403; 530/405; 530/409		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
27		☐
28		☐
29		☐
30		☐
31		☐
32		☐
33		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
34	☒	☐	US 5849800 A	19981215		Use of amantadine for treatment of Hepatitis C	514/647
35	☒	☐	US 5849860 A	19981215		Polyethylene-protein conjugates	528/370
36	☒	☐	US 5857992 A	19990112		Device and method of iontophoretic drug delivery	604/20
37	☒	☐	US 5947921 A	19990907		Chemical and physical enhancers and ultrasound for transdermal drug delivery	604/22
38	☒	☐	US 5952451 A	19990914		Solution polymerization of high molecular weight poly(phosphoesters) in toluene	528/272
39	☒	☐	US 5965519 A	19991012		Covalent polar lipid conjugates with biologically-active compounds for use in salves	514/2
40	☒	☐	US 5972707 A	19991026		Gene delivery system	435/455
41	☒	☐	US 5993435 A	19991130		Device and method of iontophoretic drug delivery	604/501
42	☒	☐	US 5994388 A	19991130		Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis	514/416
43	☒	☐	US 6002961 A	19991214		Transdermal protein delivery using low-frequency sonophoresis	604/20
44	☒	☐	US 6008318 A	19991228		Two-stage solution polymerization of high molecular weight poly(phosphoesters)	528/398

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
34			Smith, Jill P.	☐	☐	☐	☐	☐	☐	☐
35	546/300; 546/301		Hakimi, John et al.	☐	☐	☐	☐	☐	☐	☐
36	607/115		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
37	601/2		Johnson, Mark E. et al.	☐	☐	☐	☐	☐	☐	☐
38			Zhao, Zhong	☐	☐	☐	☐	☐	☐	☐
39	424/450; 514/51; 514/557; 514/78; 530/300; 530/329; 530/331; 536/26.8; 544/243; 564/153		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
40	435/320.1; 435/440; 514/44		Roy, Krishnendu et al.	☐	☐	☐	☐	☐	☐	☐
41	604/20		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
42	514/417; 514/418; 514/419; 548/472; 548/473; 548/480; 548/481		Udagawa, Taturo et al.	☐	☐	☐	☐	☐	☐	☐
43	424/448; 424/449; 604/2		Mitragotri, Samir S. et al.	☐	☐	☐	☐	☐	☐	☐
44	528/400		Zhao, Zhong et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
34		☐
35		☐
36		☐
37		☐
38		☐
39		☐
40		☐
41		☐
42		☐
43		☐
44		☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
45	☒	☐	US 6018678 A	20000125		Transdermal protein delivery or measurement using low-frequency sonophoresis	604/20
46	☒	☐	US 6020144 A	20000201		Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same	435/7.22
47	☒	☐	US 6024977 A	20000215		Covalent polar lipid conjugates with neurologically active compounds for targeting	424/450
48	☒	☐	US 6025337 A	20000215		Solid microparticles for gene delivery	514/44
49	☒	☐	US 6028099 A	20000222		Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization	514/434
50	☒	☐	US 6041253 A	20000321		Effect of electric field and ultrasound for transdermal drug delivery	604/20
51	☒	☐	US 6063759 A	20000516	35	Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting	514/2
52	☒	☐	US 6093391 A	20000725	25	Peptide copolymer compositions	424/85.1

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
45	604/22		Mitragotri, Samir S. et al.	☐	☐	☐	☐	☐	☐	☐
46	424/269.1; 424/94.3; 435/245; 435/258.3; 435/91.41; 435/91.42		Gueiros-Filho, Frederico J. et al.	☐	☐	☐	☐	☐	☐	☐
47	514/2; 514/211.11 ; 514/217; 514/222.2; 514/223.5; 514/224.8; 514/227.5; 514/649		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
48	435/320.1; 435/440; 435/455		Truong, Vu L. et al.	☐	☐	☐	☐	☐	☐	☐
49	514/456; 514/912		de Juan, Jr., Eugene	☐	☐	☐	☐	☐	☐	☐
50	600/578; 604/22		Kost, Joseph et al.	☐	☐	☐	☐	☐	☐	☐
51	424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/814; 530/815		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
52	424/182.1; 424/78.18; 424/94.3; 514/3; 514/723		Kabanov, Alexander V. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
45		☐
46		☐
47		☐
48		☐
49		☐
50		☐
51	US 6063759	☐
52	US 6093391	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
53	☒	☐	US 6114355 A	20000905	25	Methods and compositions for inhibition of angiogenesis	514/323
54	☒	☐	US 6153212 A	20001128	19	Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same	424/426
55	☒	☐	US 6166173 A	20001226	39	Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same	528/398
56	☒	☐	US 6187993 B1	20010213	34	Transgenic animals as model of psoriasis	800/18
57	☒	☐	US 6190315 B1	20010220	15	Sonophoretic enhanced transdermal transport	600/309
58	☒	☐	US 6200780 B1	20010313	52	Human interferon-.epsilon.(IFN-.epsilon.), a type I interferon	435/69.51
59	☒	☐	US 6207153 B1	20010327	56	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers	424/138.1
60	☒	☐	US 6214804 B1	20010410	37	Induction of a protective immune response in a mammal by injecting a DNA sequence	514/44

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
53			D'Amato, Robert	☐	☐	☐	☐	☐	☐	☐
54	514/772.3		Mao, Hai-quan et al.	☐	☐	☐	☐	☐	☐	☐
55	424/426; 424/486; 424/78.37; 523/111; 523/113; 525/538; 528/352; 528/400; 623/924		Mao, Hai-Quan et al.	☐	☐	☐	☐	☐	☐	☐
56	435/325; 800/21; 800/22; 800/25; 800/3		Watt, Fiona M. et al.	☐	☐	☐	☐	☐	☐	☐
57	604/22		Kost, Joseph et al.	☐	☐	☐	☐	☐	☐	☐
58	424/85.4; 435/252.3; 435/252.33; 435/254.2; 435/320.1; 435/325; 435/358; 530/351; 536/23.52		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐
59	424/141.1; 424/142.1; 424/155.1; 530/387.7; 530/388.8; 530/391.1; 530/391.3; 530/391.7		Dan, Michael D. et al.	☐	☐	☐	☐	☐	☐	☐
60	435/455; 435/69.1		Felgner, Philip L. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
53	US 6114355	☐
54	US 6153212	☐
55	US 6166173	☐
56	US 6187993	☐
57	US 6190315	☐
58	US 6200780	☐
59	US 6207153	☐
60	US 6214804	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
61	☒	☐	US 6228844 B1	20010508	42	Stimulating vascular growth by administration of DNA sequences encoding VEGF	514/44
62	☒	☐	US 6228879 B1	20010508	31	Methods and compositions for inhibition of angiogenesis	514/416
63	☒	☐	US 6234990 B1	20010522	19	Ultrasound enhancement of transdermal transport	604/22
64	☒	☐	US 6277410 B1	20010821	29	Copolymer compositions for oral delivery	424/486
65	☒	☐	US 6277830 B1	20010821	13	5'-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon	514/43
66	☒	☐	US 6284473 B1	20010904	39	P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status	435/7.1
67	☒	☐	US 6299869 B1	20011009	50	Human interferon-epsilon: a type I interferon	424/85.4
68	☒	☐	US 6303344 B1	20011016	68	Methods and compositions for polypeptide engineering	435/91.1

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
61	435/455		Wolff, Jon A. et al.	☐	☐	☐	☐	☐	☐	☐
62			Green, Shawn J. et al.	☐	☐	☐	☐	☐	☐	☐
63			Rowe, Stephen et al.	☐	☐	☐	☐	☐	☐	☐
64	424/422; 514/772.1; 514/772.3		Kabanov, Alexander V. et al.	☐	☐	☐	☐	☐	☐	☐
65	424/85.4; 424/85.7; 514/2; 514/21; 514/894; 530/351		Ganguly, Ashit K. et al.	☐	☐	☐	☐	☐	☐	☐
66	436/501; 436/504; 436/536; 436/540; 436/542; 436/804; 436/811		Whitaker, John Nicholas et al.	☐	☐	☐	☐	☐	☐	☐
67	435/252.33 ; 435/320.1; 435/325; 435/358; 435/69.1; 435/69.2; 435/69.51; 514/12; 514/2; 530/350; 530/351; 536/23.1; 536/23.52		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐
68	435/252.3; 435/325; 435/6; 435/91.5; 536/23.1		Patten, Phillip A. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
61	US 6228844	☐
62	US 6228879	☐
63	US 6234990	☐
64	US 6277410	☐
65	US 6277830	☐
66	US 6284473	☐
67	US 6299869	☐
68	US 6303344	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
69	☒	☐	US 6312924 B1	20011106	44	Murine interferon-.alpha.	435/69.51
70	☒	☐	US 6319713 B1	20011120	72	Methods and compositions for polypeptide engineering	435/440
71	☒	☐	US 6322797 B1	20011127	40	Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same	424/78.37
72	☒	☐	US 6329175 B1	20011211	59	Interferon-.epsilon.	435/69.51
73	☒	☐	US 6335160 B1	20020101	71	Methods and compositions for polypeptide engineering	435/6

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
69	435/252.8; 435/254.11 ; 435/320.1; 435/325; 435/348; 435/349; 435/419; 435/70.5; 514/2; 530/351; 536/23.1; 536/23.52		Presnell, Scott R. et al.	☐	☐	☐	☐	☐	☐	☐
70	435/6; 435/91.2; 536/23.1; 536/24.3		Patten, Phillip A. et al.	☐	☐	☐	☐	☐	☐	☐
71	428/378; 442/248; 523/115; 528/398		Mao, Hai-Quan et al.	☐	☐	☐	☐	☐	☐	☐
72	435/252.3; 435/254.1; 435/255.1; 435/320.1; 435/325; 435/348; 435/349; 435/410; 530/351; 536/23.52		Conklin, Darrell C. et al.	☐	☐	☐	☐	☐	☐	☐
73	435/320.1; 435/440; 435/471; 435/69.1; 435/91.2; 536/23.1; 536/24.3; 536/24.33		Patten, Phillip A. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
69	US 6312924	☐
70	US 6319713	☐
71	US 6322797	☐
72	US 6329175	☐
73	US 6335160	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
74	☒	☐	US 6339060 B1	20020115	35	Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting	514/2
75	☒	☐	US 6355484 B1	20020312	71	Methods and compositions for polypeptides engineering	435/440
76	☐	☐	US 6362162 B1	20020326	7	CML Therapy	514/2

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
74	424/450; 435/176; 435/178; 435/179; 435/180; 435/325; 435/366; 530/300; 530/329; 530/331; 530/811; 530/813; 530/814; 530/815		Yatvin, Milton B. et al.	☐	☐	☐	☐	☐	☐	☐
75	435/6; 536/23.1; 536/24.3		Patten, Phillip A. et al.	☐	☐	☐	☐	☐	☐	☐
76			Rybak, Mary Ellen et al.	☒	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
74	US 6339060	☐
75	US 6355484	☐
76	US 6362162	☐

East, Text search: interferon and intranasal adj1 drop?

	U	1	Document ID	Issue Date	Pages	Title	Current OR
1	☐	☐	US 5240694 A	19930831	13	Combined antiviral and antimediator treatment of common colds	424/45
2	☒	☐	US 5422097 A	19950606	13	Combined antiviral and antimediator treatment of common colds	424/45
3	☐	☐	US 5474983 A	19951212	16	Method of inhibiting pro-inflammatory mediator release from basophils and mast cells	514/12
4	☐	☐	US 5492689 A	19960220	14	Combined virustatic antimediator (COVAM) treatment of common colds	424/45
5	☒	☐	US 5728680 A	19980317	92	Methods for normalizing numbers of lymphocytes	514/19
6	☒	☐	US 5770576 A	19980623	87	Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity	514/19
7	☒	☐	US 5807830 A	19980915	89	Method for treatment of purulent inflammatory diseases	514/19
8	☒	☐	US 5811399 A	19980922	99	Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants	514/19
9	☒	☐	US 6100386 A	20000808	28	Human gene/protein involved in chronic myelogenous leukemia	536/23.1

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1	424/405; 424/408; 424/434; 424/435; 424/451; 424/464; 424/489		Gwaltney, Jr., Jack M.	☒	☐	☐	☐	☐	☐	☐
2	424/405; 424/408		Gwaltney, Jr., Jack M.	☐	☐	☐	☐	☐	☐	☐
3	514/21		Kuna, Piotr et al.	☒	☐	☐	☐	☐	☐	☐
4	424/405; 424/408; 424/434; 424/435; 424/451; 424/464; 424/489; 604/291		Gwaltney, Jr., Jack M.	☒	☐	☐	☐	☐	☐	☐
5	514/11; 514/9		Morozov, Vyacheslav G. et al.	☐	☐	☐	☐	☐	☐	☐
6	514/11		Morozov, Vyacheslav G. et al.	☐	☐	☐	☐	☐	☐	☐
7	424/184.1; 424/185.1; 424/278.1; 514/15; 514/16; 514/17; 514/18		Morozov, Vyacheslav G. et al.	☐	☐	☐	☐	☐	☐	☐
8	514/11		Khavinson, Vladimir Kh. et al.	☐	☐	☐	☐	☐	☐	☐
9	435/320.1; 435/325; 435/69.1; 435/71.1; 536/22.1; 536/23.5		Carpino, Nicholas A. et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
1	US 5240694	☐
2	US 5422097	☐
3	US 5474983	☐
4	US 5492689	☐
5	US 5728680	☐
6	US 5770576	☐
7	US 5807830	☐
8	US 5811399	☐
9	US 6100386	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
10	☒	☐	US 6140064 A	20001031	32	Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3	435/7.2
11	☒	☐	US 6165476 A	20001226	19	Fusion proteins with an immunoglobulin hinge region linker	424/195.11
12	☒	☐	US 6184358 B1	20010206	50	IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor	530/388.22
13	☒	☐	US 6329159 B1	20011211	44	Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function	435/7.24
14	☐	☐	US 6329510 B1	20011211	35	Anti-CCR1 antibodies and methods of use therefor	530/388.22

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
10	435/325; 435/7.1; 530/350; 530/351; 530/387.9		Loetscher, Marcel et al.	☐	☐	☐	☐	☐	☐	☐
11	424/85.2; 435/252.3; 435/320.1; 435/325; 435/69.7; 530/351; 530/387.3; 530/399; 536/23.4		Strom, Terry B. et al.	☐	☐	☐	☐	☐	☐	☐
12	435/326; 435/7.1; 530/387.1; 530/387.9; 530/388.1		Loetscher, Marcel et al.	☐	☐	☐	☐	☐	☐	☐
13	424/133.1; 424/139.1; 424/143.1; 435/328; 435/331; 435/334; 435/810; 435/975; 530/387.3; 530/387.9; 530/388.22; 530/389.1		Andrew, David P. et al.	☐	☐	☐	☐	☐	☐	☐
14	424/143.1; 424/144.1; 435/7.92		Qin, Shixin et al.	☒	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
10	US 6140064	☐
11	US 6165476	☐
12	US 6184358	☐
13	US 6329159	☐
14	US 6329510	☐

East: recombinant adj1 interferon and polyvinyl/prro lone

	U	1	Document ID	Issue Date	Pages	Title	Current OR
1	☒	☐	US 4636383 A	19870113	6	Interferon-cyclaradine combination	424/85.7
2	☒	☐	US 5086044 A	19920204	6	Treatment of human viral infections	514/51
3	☒	☐	US 5093114 A	19920303	6	Treatment of human viral infections	424/85.4
4	☒	☐	US 5093116 A	19920303	10	Method of treating viral infection utilizing inteferon .alpha. and pipyridamole	424/85.7
5	☒	☐	US 5198350 A	19930330	19	Interferon-induced human protein in pure form, monoclonal antibodies thereto and test kits containing these antibodies	435/91.41
6	☒	☐	US 5466585 A	19951114	22	Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies	435/69.1
7	☒	☐	US 5496266 A	19960305	14	Device and method of iontophoretic drug delivery	604/20
8	☒	☐	US 5647844 A	19970715	13	Device and method of iontophoretic drug delivery	604/20
9	☒	☐	US 5739290 A	19980414	20	Monoclonal antibody against an interferon-induced human protein in pure form	530/388.2
10	☒	☐	US 5780597 A	19980714	71	Monoclonal antibodies to cytotoxic lymphocyte maturation factor	530/388.23
11	☒	☐	US 5849800 A	19981215	9	Use of amantadine for treatment of Hepatitis C	514/647
12	☒	☐	US 5857992 A	19990112	13	Device and method of iontophoretic drug delivery	604/20
13	☒	☐	US 5869264 A	19990209	21	Immunoassays for and immunopurification of interferon-induced human protein	435/7.1

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1	424/85.4; 435/71.1		Nagabhushan, Tattanahali L. et al.	☐	☐	☐	☐	☐	☐	☐
2	514/934		Rideout, Janet L. et al.	☐	☐	☐	☐	☐	☐	☐
3	424/85.5; 424/85.7; 514/5		Rideout, Janet L. et al.	☐	☐	☐	☐	☐	☐	☐
4	514/262.1; 514/889		Suzuki, Nobuo	☐	☐	☐	☐	☐	☐	☐
5	435/488; 435/91.51; 435/91.53; 530/350; 530/387.9; 530/388.2; 536/23.5		Horisberger, Michel A. et al.	☐	☐	☐	☐	☐	☐	☐
6	435/252.3; 435/252.33 ; 435/320.1; 536/23.1; 536/23.5		Horisberger, Michel A. et al.	☐	☐	☐	☐	☐	☐	☐
7	604/19		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
8	424/449		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
9	435/331; 435/69.1; 530/388.1; 530/391.1		Horisberger, Michel Andre et al.	☐	☐	☐	☐	☐	☐	☐
10	530/351; 530/387.1; 530/389.2; 530/806		Gately, Maurice Kent et al.	☐	☐	☐	☐	☐	☐	☐
11			Smith, Jill P.	☐	☐	☐	☐	☐	☐	☐
12	607/115		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
13	530/388.1		Horisberger, Michel Andre et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
1	US 4636383	☐
2	US 5086044	☐
3	US 5093114	☐
4	US 5093116	☐
5	US 5198350	☐
6	US 5466585	☐
7	US 5496266	☐
8	US 5647844	☐
9	US 5739290	☐
10	US 5780597	☐
11	US 5849800	☐
12	US 5857992	☐
13	US 5869264	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
14	☒	☐	US 5981277 A	19991109	76	Polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology	435/325
15	☒	☐	US 5993435 A	19991130	13	Device and method of iontophoretic drug delivery	604/501
16	☒	☐	US 6133309 A	20001017	11	Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists	514/432
17	☒	☐	US 6153212 A	20001128	19	Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same	424/426
18	☒	☐	US 6200780 B1	20010313	52	Human interferon-.epsilon.(IFN-.epsilon.), a type I interferon	435/69.51
19	☒	☐	US 6299869 B1	20011009	50	Human interferon-epsilon: a type I interferon	424/85.4

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
14	435/252.3; 435/252.33; 435/254.11; 435/320.1; 435/364; 435/367; 435/455; 536/23.1; 536/23.5; 536/24.1; 536/24.33		Fransen, Lucia et al.	☐	☐	☐	☐	☐	☐	☐
15	604/20		Haak, Ronald P. et al.	☐	☐	☐	☐	☐	☐	☐
16			Bollag, Werner et al.	☐	☐	☐	☐	☐	☐	☐
17	514/772.3		Mao, Hai-quan et al.	☐	☐	☐	☐	☐	☐	☐
18	424/85.4; 435/252.3; 435/252.33; 435/254.2; 435/320.1; 435/325; 435/358; 530/351; 536/23.52		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐
19	435/252.33; 435/320.1; 435/325; 435/358; 435/69.1; 435/69.2; 435/69.51; 514/12; 514/2; 530/350; 530/351; 536/23.1; 536/23.52		Chen, Jian et al.	☐	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
14	US 5981277	☐
15	US 5993435	☐
16	US 6133309	☐
17	US 6153212	☐
18	US 6200780	☐
19	US 6299869	☐

	U	1	Document ID	Issue Date	Pages	Title	Current OR
20	☒	☐	US 6312924 B1	20011106	44	Murine interferon-.alpha.	435/69.51
21	☒	☐	US 6322797 B1	20011127	40	Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same	424/78.37
22	☒	☐	US 6326388 B1	20011204	14	Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level	514/364
23	☒	☐	US 6326397 B1	20011204	24	Retinoid antagonists and use thereof	514/531
24	☒	☐	US 6329175 B1	20011211	59	Interferon-.epsilon.	435/69.51
25	☒	☐	US 6329381 B1	20011211	66	Heterocyclic compounds	514/263.23
26	☐	☐	US 6344464 B1	20020205	14	Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination	514/315

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
20	435/252.8; 435/254.11 ; 435/320.1; 435/325; 435/348; 435/349; 435/419; 435/70.5; 514/2; 530/351; 536/23.1; 536/23.52		Presnell, Scott R. et al.	☐	☐	☐	☐	☐	☐	☐
21	428/378; 442/248; 523/115; 528/398		Mao, Hai-Quan et al.	☐	☐	☐	☐	☐	☐	☐
22	546/134; 548/131		Man, Hon-Wah et al.	☐	☐	☐	☐	☐	☐	☐
23	514/502; 514/570; 554/218; 560/55; 560/59; 562/465; 562/469; 568/442		Bollag, Werner et al.	☐	☐	☐	☐	☐	☐	☐
24	435/252.3; 435/254.1; 435/255.1; 435/320.1; 435/325; 435/348; 435/349; 435/410; 530/351; 536/23.52		Conklin, Darrell C. et al.	☐	☐	☐	☐	☐	☐	☐
25	514/263.36 ; 514/263.4		Kurimoto, Ayumu et al.	☐	☐	☐	☐	☐	☐	☐
26	514/318		Bourrie, Bernard et al.	☒	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
20	US 6312924	☐
21	US 6322797	☐
22	US 6326388	☐
23	US 6326397	☐
24	US 6329175	☐
25	US 6329381	☐
26	US 6344464	☐

East: Inventors' name search (Petr near Gaponjuk.in.) or (Elena near Markova.in.)

	U	1	Document ID	Issue Date	Pages	Title	Current OR
1	☐	☐	EP 437636 A1	19910724	10	DEVICE FOR LOCATING AND INFLUENCING ACUPUNCTURE POINTS.	

	Current XRef	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1			ZHUKOV, DMITRY SERGEEVICH et al.	☒	☐	☐	☐	☐	☐	☐

	Image Doc. Displayed	PT
1	EP 437636 A1	☐